Introduction

Welcome to the official page for the Clinical Practice Guidelines on Best Practices for the use of small molecules and anti-IL-23p19 inhibitors in the treatment of ulcerative colitis and Crohn's disease. This initiative, led by the Asia Pacific Association of Gastroenterology (APAGE) Working Group for IBD in collaboration with the Asian Education Network for IBD (AEN-IBD), aims to standardize care, improve patient outcomes, and address the unique challenges faced by healthcare professionals in the Asia-Pacific region.

About the Consensus

The primary goal of this consensus meeting is to develop comprehensive and evidence-based Clinical Practice Guidelines for the use of small molecules and anti-IL-23p19 inhibitors in the treatment of ulcerative colitis and Crohn's disease. The consensus will be developed using the modified Delphi method and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to ensure a rigorous and transparent process.

What You Need to Do

We are currently initiating the first round of voting for the consensus. There are a total of 33 statements, please review them and rate your agreement on each statement.

The agreement level will be as follows:
1 = Reject Completely
2 = Reject with reservation
3 = Accept with major reservation
4 = Accept with some reservation
5 = Accept completely

A statement will only be accepted if more than 80% of the voting panel voted 4 or 5.

Please leave your comments, if any, for each statement in the box provided. Your feedback is essential for refining and finalizing these guidelines.

When you are ready to start the voting, click on the "Start" button. The voting process is estimated to take approximately 30 minutes.

Voting will be anonymous. Your identity will not be linked to your individual votes, and your voting choices will remain confidential.

Thank you for your valuable contribution to this important initiative. As an esteemed member of the voting panel, your participation is crucial in shaping these guidelines.